SHUANGYUN BIOMED

SHUANGYUN BIOMED (Suzhou) Co., Ltd. owns an AI-assisted new drug R&D platform, including: Big Data AI-assisted forward screening technology, Big Data AI-assisted reverse screening technology, and drug-likeness prediction technology; a virtual diverse compound library (1.2 billion compounds); a co-crystal protein structure library (250,000 protein crystals); a reverse docking database of all FDA-approved drugs, etc. The company utilizes its proprietary AI drug discovery platform to carry out new drug discovery work targeting a series of difficult-to-drug targets and has achieved phased progress.